IGF1-Targeting Teprotumumab Tackles Thyroid Eye Disease

Source: Medscape

Patients with moderate to severe thyroid-associated ophthalmopathy show significant improvements with treatment with teprotumumab (River Vision Development) extending as far out as 72 weeks, according to a report in Medscape.

“We found that most proptosis (eye bulging) responders receiving teprotumumab maintained a response at 1 year off the drug and adverse events were moderate and transient,” said George J. Kahaly, MD, PhD, of the Department of Medicine, Johannes Gutenberg University Medical Center, Mainz, Germany, who reported the findings here at the 2018 Annual Meeting of the American Thyroid Association (ATA).

“The results show that teprotumumab treatment in patients with thyroid eye disease was efficient and safe, and it’s important…this is the first time we are dealing with a disease-modifying drug.”

Read the full article.

Related Content